Detection of protein disease markers using long-range surface plasmon waveguides

目前可用的即时生物检测系统提供与血液化学/电解质、血液学、血气、凝血和心脏标志物相关的血液分析结果。商业系统中使用的核心技术是基于电化学转导，尽管方便，但其特异性和灵敏度有限。这些限制阻碍了市场扩展到许多疾病的标志物检测。因此，人们对新的检测技术产生了浓厚的兴趣，这些技术将提高在护理点进行的测试的灵敏度和特异性。分析物的检测，例如，心肌肌钙蛋白I（c-TnI，心肌梗塞标记物）降低到低浓度水平引起了强烈的兴趣。该项目中要解决的公司特定问题包括检测低浓度的蛋白质疾病标志物，如c-TnI，最初在清洁液体中，然后在复杂液体中，如血浆。我们的工业合作伙伴将 通过开发和应用新的生物检测方法和技术来解决与医学界高度相关的问题，从该项目中受益。最终，向合作伙伴转让技术将导致向新市场的扩展，为加拿大带来经济利益。

Currently available point-of-care bio-detection systems provide blood analysis results relevant to blood chemistry/electrolytes, hematology, blood gases, coagulation and cardiac markers. The core technology used in commercial systems is based on electrochemical transduction, and although convenient, it is limited in specificity and sensitivity. These limitations preclude market expansion into the detection of markers for many diseases. Thus, there is a strong interest in new detection technologies that will improve sensitivity and specificity of tests carried out at the point of care. The detection of analyte, e.g., cardiac troponin I (c-TnI, a myocardial infarction marker), to low concentration levels is of strong interest. The company-specific problem to be addressed in this project consists of detecting a protein disease marker, such as c-TnI, to low concentrations, initially in clean fluids, then in complex fluids such as blood plasma. Our industrial partner will benefit from this project through the development and application of new bio-detection approaches and technologies to a problem of high relevance to the medical community. Ultimately, transfer of the technology to the partner would lead to expansion into new markets producing economic benefits to Canada.